Multiple Myeloma Hub

A global online platform providing the latest treatment options & medical information on multiple myeloma #mmsm #myeloma

[Multiple Myeloma Hub @MM_Hub]

Find out how ocular events associated with belantamab mafodotin in the DREAMM-7 and DREAMM-8 trials were effectively managed with dose modifications, including the impact on patient-reported outcomes.

Learn more: https://t.co/UPnSeqICVF

#MultipleMyeloma #myeloma #MedNews #MedEd

[Multiple Myeloma Hub @MM_Hub]

New publication 📝 We highlight key strategies for CRS risk mitigation and prophylaxis, recognition and monitoring, and management during BsAb treatment for RRMM in community practice.

Learn more: https://t.co/RtFiAW043X

#myeloma #mmsm #MedNews #MedEd

[Multiple Myeloma Hub @MM_Hub]

It’s the final day of live event coverage.

We have really enjoyed covering the oncology congress and bringing you the live coverage!

You can catch up on anything you have missed, by visiting the Multiple Myeloma Hub now.

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | POSTER

Güldane Cengiz-Seval presents results from an analysis of the phase III DREAMM-8 trial, evaluating PFS2 outcomes by prior therapy in patients with relapsed/refractory #MultipleMyeloma treated with BPd (n = 155) or PVd (n = 147).

PFS2 benefit with BPd vs PVd was maintained across prior-therapy subgroups, including patients who were Len-refractory and anti-CD38-exposed/refractory (HR, 0.63; 95% CI, 0.36–1.12). In Len-refractory patients, median PFS2 was 41.7 vs 15.0 months, respectively (HR, 0.49; 95% CI, 0.35–0.68). Median PFS2 was numerically longer in patients who received novel therapies vs non-novel agents as first subsequent therapy (26.0 vs 20.1 months; HR, 0.61; 95% CI, 0.34–1.09).

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @gdnsvl @AnkaraUni @AnkaraUni_en

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | POSTER

Xavier P. Leleu discusses results from a cross-trial analysis evaluating the safety and reliability of isatuximab (Isa) subcutaneous (SC) on-body injector (OBI) in patients with relapsed/refractory #MultipleMyeloma across the phase III IRAKLIA (N = 263), phase II IZALCO (N = 64), and phase Ib TCD15484 (N = 22) trials.

Across trials, median Isa SC OBI injection duration was 12.0 min. Infusion-related reactions (IRRs) occurred in 0.09% of 6,426 injections and 1.15% of 349 patients, with no discontinuations due to IRRs. Overall, 99.9% of injections were completed without interruption, and local injection-site reactions (ISRs) occurred in 6.02% of patients, mostly Grade 1.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @CHU_de_Poitiers

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | POSTER

Preetinder Singh Manshahia shares results from a TriNetX retrospective cohort analysis evaluating outcomes after ide-cel or cilta-cel in patients with relapsed/refractory #MultipleMyeloma with baseline renal dysfunction (creatinine ≥2.0 mg/dL, not on dialysis) vs preserved renal function (creatinine ≤1.0 mg/dL) (N = 158; n = 79 per propensity-matched cohort).

Early CRS incidence (Days 0–15) was similar in patients with vs without baseline renal dysfunction (33.3% vs 36.5%), and no patients developed DIC or required dialysis. Mortality was significantly higher in patients with baseline renal dysfunction at 6 months (40% vs 13.2%), 1 year (45.3% vs 15.8%), and 3 years (52% vs 21.1%) (all p < 0.001). Among patients with baseline renal dysfunction and 90-day follow-up (n = 61), renal recovery occurred in 78.7% by creatinine criteria and 62.3% by eGFR criteria.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @PreetinderSMans @ROCRegional

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | POSTER

Hans C. Lee shares findings from an updated MAIC comparing linvoseltamab vs teclistamab in patients with triple-class exposed relapsed/refractory #MultipleMyeloma using LINKER-MM1 patient-level data (n = 107; effective sample size, 82.5) and MajesTEC-1 aggregate data (n = 165). Restricted mean survival time (RMST) was evaluated at 30 months.

After adjustment for six key prognostic factors, linvoseltamab showed significantly longer DoR (HR, 0.54; RMST difference, +4.06 months), PFS (HR, 0.55; RMST difference, +5.43 months), OS (HR, 0.64; RMST difference, +3.06 months), and TTNT (HR, 0.41; RMST difference, +7.12 months) vs teclistamab (all p < 0.05). Response rates numerically favored linvoseltamab, including ORR (OR, 1.50), ≥VGPR (OR, 1.17), and ≥CR (OR, 1.21).

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @SarahCannonDocs

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Meletios A. Dimopoulos presents updated results from phase III DREAMM-8 evaluating long-term outcomes with sustained MRD negativity following BPd vs PVd in patients with relapsed/refractory #MultipleMyeloma (N = 302; BPd, n = 155; PVd, n = 147).

In the ITT population, MRD negativity was achieved in 64.2% with BPd vs 36.0% with PVd; MRD negativity sustained ≥12 months was achieved in 15.5% vs 2.7%, respectively. Among patients with sustained MRD negativity, median PFS and PFS2 were NR in both arms; 24-month PFS and PFS2 rates were 100% with both BPd and PVd. In patients without sustained MRD negativity, median PFS and PFS2 were longer with BPd vs PVd: 21.1 vs 10.2 months and 20.2 vs 9.3 months, respectively. BPd-treated patients maintained MRD negativity for up to 4 years, with follow-up ongoing.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @thanosdimop @uoaofficial

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Prashant Kapoor discusses results from the phase I/II IDEAL study evaluating iberdomide + daratumumab + bortezomib + dexamethasone (Iber-DVd) in patients with transplant-deferred or transplant-ineligible newly diagnosed #MultipleMyeloma (N = 44).

Patients received fixed-duration Iber-DVd induction followed by Iber maintenance. The RP2D of iberdomide was 0.75 mg/day, D1-21. The ORR was 100%, with CR reported in 57% of patients by mass spectrometry-based assessment; MRD negativity at 10⁻⁵ was achieved in 52%. At a median follow-up of 22.8 months, 12- and 18-month PFS rates were 92.0% and 88.9%, respectively; corresponding OS rates were 97.4% and 94.5%, respectively. The most common Grade 3/4 TEAEs were neutropenia and lymphopenia, with no new safety signals reported.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @MyelomaDrKapoor @MayoClinic @MayoCancerCare

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Saad Z. Usmani presents final results from a post hoc analysis of the phase III CEPHEUS trial, evaluating Dara-VRd vs VRd in patients with transplant-ineligible newly diagnosed #MultipleMyeloma (N = 289; Dara-VRd, n = 144; VRd, n = 145).

At a median follow-up of 76.0 months, overall MRD negativity at 10⁻⁵ was higher with Dara-VRd vs VRd (61.1% vs 40.0%; OR, 2.35; p = 0.0004). Sustained MRD negativity at 10⁻⁵ also favored Dara-VRd vs VRd at ≥12 months (49.3% vs 29.0%; OR, 2.40; p = 0.0005) and ≥24 months (44.4% vs 23.4%; OR, 2.62; p = 0.0002). Similar results were seen at a sensitivity threshold of 10⁻⁶. At 72 months, PFS was 59.3% with DVRd vs 38.3% with VRd; median PFS was not reached vs 50.2 months, respectively (HR, 0.55; p = 0.0007). No additional safety concerns were identified with longer follow-up.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @szusmani @MSKCancerCenter

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Evangelos Terpos presents results from the phase I/II BelaDRd study evaluating belantamab mafodotin (belamaf) + daratumumab + lenalidomide + dexamethasone in transplant-ineligible patients with newly diagnosed #MultipleMyeloma (N = 36; Part 1, n = 24, Part 2, n = 12).

The RP2D was belamaf 1.9 mg/kg Q8W. The ORR was 91.7% in both Part 1 and Part 2, with MRD negativity reported in 13/16 (81.3%) and 5/7 (71.4%) of evaluable patients, respectively. At 18 months, overall PFS was 91.7% and PFS in the RP2D population was 87.5%. Discontinuation due to AEs was <5%; no Grade 4 ocular AEs and <5% Grade 3 ocular AEs were observed.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @uoaofficial

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Timothy O’Brien presents results from a TriNetX retrospective analysis comparing CAR T-cell therapy → BiTE vs BiTE → CAR T-cell therapy sequencing in patients with relapsed/refractory #MultipleMyeloma who received both therapies (N = 389; after propensity score matching, N = 224; n = 112 per cohort).

In matched cohorts, 5-year OS was 50% with CAR T-cell therapy → BiTE vs 25% with BiTE → CAR T-cell therapy, with median OS of 5.0 vs 3.1 years, respectively. In adjusted multivariable Cox regression, CAR T-cell therapy–first sequencing was independently associated with lower 5-year mortality (HR, 0.57; 95% CI, 0.34–0.95), despite higher ide-cel use in the CAR T-cell therapy–first group (72% vs 14%).

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @UHhospitals @caseccc @cwru

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Peter Forsberg presents results from OPTec/OPTal, a phase II study evaluating outpatient step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab in patients with relapsed/refractory #MultipleMyeloma (N = 52; Tec, n = 45; Tal, n = 7).

CRS occurred in 8.9% of patients receiving Tec and 28.5% of patients receiving Tal; no Grade 3/4 CRS or ICANS was reported in either arm. The most common Grade ≥3 events across both arms were neutropenia (n = 13), sepsis (n = 4), and anemia (n = 4). The ORR was 68.9% with Tec and 71.4% with Tal.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @ForsbergMD @ColoradoBlood

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO26 | PRESENTATION

Phoebe Joy Ho presents updated results from inMMyCAR, an ongoing first-in-human phase I study evaluating KLN-1010, an in vivo anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory #MultipleMyeloma (N = 18).

The ORR was 100%, and BM MRD-negative responses were observed in 100% of MRD-evaluable patients (n = 14). Responses deepened over time, with earliest treated patients in ongoing response at and beyond 9 months post-dosing. Robust CAR-T persistence in the absence of lymphodepletion was observed. CRS occurred in 15/18 patients, all Grade 1–2. One case of Grade 3 ICANS was reported; this was limited to 3 days, and no delayed neurotoxicity was observed in any patient.

Follow our live feed for more updates: https://t.co/h4gRc4TWUv

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma #MedEd #MedicalCongress @SydneyLHD @Sydney_Uni

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO2026 | PRESENTATION

Jennifer Cooperrider shares findings from a phase II Multiple Myeloma Research Consortium study, evaluating daratumumab + carfilzomib + pomalidomide + dexamethasone in R/R MM (N = 28).

At a median follow-up of 70.2 months, the ORR was 89.6%. The median PFS was 38.4 months and the median OS was NR. The 36-month PFS and OS rates were 54% and 75%, respectively. The median PFS and OS in patients with high-risk cytogenetics were 18.4 months and 41.9 months, respectively, and were 59.4 months and NR in patients with standard-risk cytogenetics. Grade ≥3 infections occurred in 32% of patients.

Follow our live feed for more updates: https://t.co/I2Plv0Urjn

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma @UChicago

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO2026 | PRESENTATION

Sikander Ailawadhi discusses findings from a subgroup analysis of the phase III IRAKLIA trial, evaluating isatuximab + pomalidomide-dexamethasone in patients with R/R MM with/without prior anti-CD38 exposure (N = 531).

Overall, 12.6% of patients had prior anti-CD38 exposure. Patients with prior anti-CD38 exposure had an ORR of 52.2% and a 12-month PFS rate of 40.6%. Patients without prior anti-CD38 exposure had an ORR of 73.5% and a 12-month PFS rate of 68.8%. A longer washout period (>20.2 months) between anti-CD38 therapies was associated with a greater ORR (63.6% vs 41.2%) and greater rates of 12-month PFS (61.8% vs 19.2%). The safety profile of isatuximab + pomalidomide-dexamethasone was similar between patients with and without prior anti-CD38 exposure.

Follow our live feed for more updates: https://t.co/I2Plv0Urjn

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma @MayoClinic

[Multiple Myeloma Hub @MM_Hub]

We are entering Day 4 of live congress coverage!

If you would like to catch up on our coverage from the oncology congress event, visit the Multiple Myeloma Hub, where you can view our live congress feed.

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASCO2026 | PRESENTATION

Suzanne Lentzch presents the 2026 highlights in immunotherapy advances for plasma cell disorders from this year’s congress. Key trials include the ERASMM/EMN34 study of elranatamab in high-risk smoldering MM, the DREAMM-9 study of BVRd in transplant ineligible ND MM, the MajesTEC-9 study of teclistamab vs PVd/Kd in anti-CD38 + LEN exposed R/R MM, and the SUCCESSOR-2 study of MeziKd vs Kd in anti-CD38 + LEN exposed R/R MM.

Follow our live feed for more updates: https://t.co/I2Plv0Urjn

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#mmsm #myeloma @Columbia @SLentzsch

[Multiple Myeloma Hub @MM_Hub]

It’s Day 3 of the Multiple Myeloma Hub’s oncology congress coverage!

If you have missed our live coverage from the event so far, you can catch up now on our live congress feed – available on the Multiple Myeloma Hub.

[Multiple Myeloma Hub @MM_Hub]

It’s Day 2!

Catch up on the latest developments in multiple myeloma, via the Multiple Myeloma Hub’s oncology congress feed.